Study:
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Rationale:
Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as trastuzumab and bevacizumab, can block tumor growth
in different ways. Some block the ability of tumor cells to grow and spread. Others find
tumor cells and help kill them or carry tumor-killing substances to them. Giving
chemotherapy together with monoclonal antibody therapy may kill more tumor cells.
Purpose:
This clinical trial is studying how well giving docetaxel and carboplatin together
with trastuzumab and bevacizumab works in treating patients with stage I, stage II, or stage
III breast cancer and bone marrow micrometastases.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Breast Cancer |
Biological: bevacizumab
Biological: trastuzumab
Drug: carboplatin
Drug: docetaxel
Other: laboratory biomarker analysis |
Phase 0 |
Verified by
Case Comprehensive Cancer Center
April, 2013
Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00949247
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Joseph Baar, MD, PhD., Principal Investigator
Thomas Budd, MD., Principal Investigator